

## ABSTRACT TEMPLATE: CHECKLIST AND INSTRUCTIONS

Company name Cytora \* Website <https://www.cytorastem.com/>

CEO name Yona Geffen\*

CATEGORY: Biotech/Pharma \*

SESSIONS : Personalized Pathways; Genetic and cellular based Advances for Rare and Complex Disease

Title: Harnessing the Unique Healing Potential of Human Oral Mucosa Stem Cells for Treating Complex Multifactorial Diseases

- Executive Summary

Cytora is a clinical stage stem cell company developing a new class of products based on human oral mucosa (hOMSC) stem cells. Cytora's products are allogeneic, off-the-shelf, easily scalable, with a very competitive COG. The products were found to be safe and effective in early clinical trials in two indications: Diabetic Foot Ulcers (DFU) and Multiple System Atrophy (MSA).

- Core Technology

Cytora's technology is based on the discoveries of Prof. Sandu Pitaru, Tel-Aviv university. The technology is based on a novel and unique stem cell population in the human oral mucosa, originated from the embryonic nervous system. hOMSC retain properties of neural crest and mesenchymal stem cells, making them effective and superior to other stem cells in targeting multifactorial diseases.

- Product Profile/Pipeline

Cytora's pipeline products include 2 indications in early clinical stage; hard-to-heal DFU, and MSA. Other indications are at preclinical stages and include neurodegenerative diseases such as Parkinson and Alzheimer's Disease and autoimmune diseases such as psoriasis. Phase 2 clinical trials under FDA IND are planned for DFU and MSA. Studies to initiate in Q4 2025 and Q2 2026 respectively.

- Business Strategy

The company is initiating a financial round to fund clinical programs and achieve key milestones. Concurrently, it is pursuing strategic partnerships with major pharmaceutical companies. The Israeli Innovation Authority is providing support across various company initiatives.

- What's Next?

Cytora plans a Pre-IND meeting with the FDA for Phase 2 DFU clinical trial in Q3 2025 and a Type C meeting for MSA in Q4 2025. IND-enabling studies are

ongoing in Cytora's new GMP facility. The financing round is seen as a pivotal milestone, paving the way for an IPO, M&A, or strategic partnerships.